Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.

@article{Harnett2007PhaseIS,
  title={Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.},
  author={Paul Harnett and Michael T. Buck and Philip Beale and A J Goldrick and S Hoffman Allan and Bernie Fitzharris and Paul de Souza and Matthew Jon Links and Ghulam Kalimi and Timothy J. Davies and Robin C. Stuart-Harris},
  journal={International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  year={2007},
  volume={17 2},
  pages={
          359-66
        }
}
Gemcitabine and oxaliplatin have shown single-agent activity in relapsed ovarian cancer. This combination was used to determine response rates, time-to-event efficacy measures, and toxicity in patients with recurrent ovarian cancer. Patients with prior platinum-based chemotherapy who had measurable lesions and/or elevated CA-125 levels were identified as group A (platinum-refractory/platinum-resistant patients) and group B (platinum-sensitive patients). All patients received gemcitabine 1000 mg… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Similar Papers

Loading similar papers…